E nd-of-life care refers to the care of patients with progressive, incurable conditions and considered to be in the last year of life. Approximately 75% of end-of-life patients will die from non-malignant conditions. There are significant challenges, both in the identification of patients with chronic disease who are nearing the end of life and in the provision of high-quality palliative care in this group. This article explores the role of GPs in the management of end-of-life care in the most common non-malignant conditions, including management of symptoms and advance care planning.
based on the WHO ICD-10 classification shows that deaths from dementia and Alzheimer's disease are increasing. Primarily this is believed to be the result of an ageing population, but also to a greater awareness and diagnosis of dementia. Table 1 shows the leading causes of death from non-malignant diseases in males and females in 2014.
Barriers to providing end-of-life care
It is well known that early identification of patients who are near the end of life ensures they are more likely to have access to high-quality palliative care (Thoonsen et al., 2016) . The Dying Matters Campaign's 'find your 1%' (www.dyingmatters.org) encourages GPs to identify the 1% of practice patients expected to die within the next year, and highlights that approximately 75% of these deaths will be from nonmalignant conditions. Asking the question 'Would you be surprised if this patient died within the next year?' is often helpful when considering whether a patient is near the end of their life. Practices should have a palliative care register of patients who have been identified as nearing the end of their life. However, the National Primary Care Snapshot Audit (2009) in England found that only 25% of patients who died were included on the register, and only 25% of patients on the register had non-malignant conditions.
Uncertain disease trajectory
One of the key difficulties in identifying patients who are near the end of their life is the erratic and unpredictable decline that is often seen in nonmalignant disease and a lack of clear transition into the terminal phase. Figure 1 illustrates the commonly seen differences in disease trajectory.
Cancer patients are likely to have a more predictable disease trajectory of slow decline followed by a transition to a terminal phase of more rapid steady deterioration. In contrast, the slow decline in patients with conditions leading to single organ failure, such as chronic obstructive pulmonary disease (COPD), heart failure or renal failure is interrupted by intermittent exacerbations. During exacerbations there can be very significant functional impairment with the risk of a sudden death, or partial recovery with some level of irreversible damage. It is difficult to know which exacerbation will be the last, so in the end, death may be unexpected with little or no preparation beforehand. Prolonged and slow decline can also be seen, particularly in frailty or dementia patients with multiple comorbidities and organ failure.
The Gold Standards Framework is an initiative that started in 2000 and provides a validated foundation for delivering high-quality care for patients in the last years of life. To support clinicians in identifying patients entering the terminal phase of their illness the Gold Standards Framework has produced Proactive Identification Guidance (PIG).
This consists of a set of general indicators of decline that include repeated hospital admissions, advanced disease, decreasing activity, decreasing response to treatment, weight loss (more than 10% in 6 months) and low serum albumin. More specific indicators for different diseases that suggest a patient may be entering the last 12 months of life are also given. Those for the more common non-malignant conditions are shown in Box 1. A full list of specific clinical indicators for different conditions including kidney and liver disease, neurological diseases and stroke are also available. In all cases decision-making should take into account clinical findings, pathology, response to treatment, co-morbidities and psychosocial factors.
Patient and physician factors
Patients with non-malignant disease often have a poor understanding of their illness. The gradual onset of symptoms can mean that few are able to remember the point at which they are diagnosed, and many with organ failure do not appreciate that their condition is life-limiting ). This contrasts with a diagnosis of cancer, where there is a greater public understanding that this illness causes death and acceptance by patients and relatives of the likely course of events . This means that it can be more difficult for physicians to initiate discussions about palliative care in a timely manner.
Box 1. Gold Standards Framework PIG. Specific clinical indicators

Heart disease
At least two of the indicators below:
. Patient for whom the surprise question is applicable
. New York heart association (CHF NYHA) Stage 3 or 4 heart failure with ongoing symptoms despite optimal therapy
. Repeated admissions with heart failure: Three admissions in 6 months or a single admission aged over 75 years . Difficult ongoing physical or psychological symptoms despite optimal tolerated therapy . Additional features include hyponatraemia, high blood pressure, declining renal function, anaemia, etc.
COPD
. where a patient often has a longstanding relationship with their GP, are preferred. Waiting for an exacerbation to prompt discussions is to be avoided (Gott et al., 2016) .
Symptom control
There is considerable overlap between symptoms experienced by patients in the end of life with malignant and non-malignant conditions. Such patients are often on a large number of medicines and rationalisation of regular medications by stopping non-essential prescriptions to reduce tablet burden and the risk of side effects is very important.
Heart failure
Patients with end-stage heart failure suffer a symptom burden that is often greater than those with advanced cancer 
Respiratory disease
Most deaths from chronic lower respiratory tract disease are caused by COPD. COPD is a chronic airways disease that is characterised by progressive functional decline and worsening symptoms. Patients with COPD often have other coexisting problems such as heart disease, lung cancer or cerebrovascular disease. Symptom burden is high, with the main concern being breathlessness: 94% of patients with advanced COPD reporting moderate-to-severe breathlessness .
There is also a high incidence of anxiety, depression, pain, anorexia and fatigue among COPD patients (Traue & Ross, 2005) . Liaising with respiratory consultants and COPD nurse specialists to maximise inhaler therapy is important. Opioids can be used to treat refractory dyspnoea as well as the non-pharmacological techniques previously mentioned for heart failure.
Where there are thick secretions, nebulised saline can help.
Hyoscine hydrobromide via patch or syringe driver, or Hyoscine butylbromide via syringe driver can be used for copious secretions, but these may cause sedation. Glycopyrronium is a good alternative if sedation is not desired.
The evidence for the role of oxygen in helping breathlessness is inconclusive. If oxygen saturations are less than 90% it may be beneficial, however, some patients find the burden of being attached to the oxygen outweighs the benefits. Great care needs to be taken in giving oxygen to COPD patients who are at risk of carbon dioxide retention.
Pulmonary rehabilitation programmes run by physiotherapists and specialist nurses teach patients breathing and relaxation exercises and provide counselling on other lifestyle measures and adaptations that patients can make to improve their symptoms.
Frailty
Frailty is defined as 'a distinctive health state related to the ageing process in which multiple body systems gradually lose their in-built reserves' (British Geriatrics Society, 2014) . Unintentional weight loss, reduced muscle strength and loss of muscle, reduced gait speed, and self-reported exhaustion are all key features. Twenty-six per cent of InnovAiT people over the age of 85 meet the criteria for a diagnosis of frailty 
Dementia
It is important to start discussions around palliative care and advanced care planning early with patients with dementia at a time they have sufficient mental capacity to make and express wishes about future treatment. Involvement of next of kin is important, as is a discussion about whether, if they have the capacity to do so, they want to put in place a Lasting Power of Attorney document.
Symptoms with dementia such as pain, pressure sores and agitation can be harder to identify, as patients are often unable to communicate their symptoms. Therefore, a good history from carers and relatives and assessment of non-verbal signs of distress is needed. Urinary incontinence is common, and can lead to skin breakdown and pressure sores. Advice from a continence specialist is often helpful in preventing this problem.
Patients with dementia are more likely to experience behavioural problems such as agitation, aggression or psychosis towards the end of life. It is important to distinguish between symptoms of disease progression and those from reversible factors such as pain, constipation, infection or side effects of medication.
Patients with dementia are more likely to die in a care home or nursing home and much less likely to die in a hospice . This may be because these settings are most appropriate for care of a particular individual, but patients wishing to die at home need access to appropriate home care support to allow this to occur. The burden on carers of patients with advanced dementia is high, and access to financial advice, social support and psychological support is crucial.
Advance care planning 
Preferred place of death
Where the individual dies is an important aspect of end-of-life care and is significant for both the patient and family. Most people when asked express a preference to die at home rather than in hospital . A study looking at place of death in a group of palliative patients found that 75% of those with an active care plan specifying preferred place of death died in their place of choice, whereas patients whose preferred place of death was unknown were more likely to die in hospital (Ali, Capel, Jones, & Gaazi, 2015) .
Those who die from non-malignant diseases are less likely to have a recorded preference for place of death. Other factors associated with lower rates of recording for preferred place of death were the patient living in an area of significant deprivation, not having a spouse or partner, and being from Black, Asian or other minority ethnic group . Figure 2 shows the trends in place of death in England over time.
This shows a gradual increase in deaths in the usual place of residence (home or care home) mirrored by a reduction in deaths in hospital.
However, many more patients still die in hospital compared with those that express a wish to do so.
Discussions around preferred place of death with patients need to consider the support required. Patients with complex medical requirements such as PEG tubes and long-term oxygen therapy, or those InnovAiT needing a high level of care, need placing where these can be provided. The preferred place of care needs to be reassessed as patients' wishes and needs change over time.
Advance decisions on treatment
When considering future care patients may consider preferences for care, different treatments and interventions. Certain diagnoses will prompt specific questions. Patients with heart failure may have cardiac defibrillators and need to discuss when to deactivate the defibrillator.
Decisions about non-invasive ventilation may be needed for patients with COPD or motor neurone disease. Patients with end-stage renal disease need to consider and discuss renal replacement therapy.
An advance decision to refuse treatment (ADRT) considers the decisions that are made while a patient still has capacity to refuse specified medical treatments at a future time when they may lack
capacity. An ADRT that is both valid and applicable is legally binding under the Mental Capacity Act of 2005.
Advanced care plans may also state patient's wishes about treatments they would want should they lose capacity. These must be considered in decisions about care in the patient's best interests, but are not legally binding.
Lasting Power of Attorney
If there are concerns that a patient may lack mental capacity in the future they can draw up a legal document called a Lasting Power of Attorney (LPA). This appoints one or more people (known as 'attorneys') to make decisions for them (the donor) should they lose capacity to do so. There are two types of Lasting Power of Attorney:
'health and welfare' and 'property and financial affairs'. If more than one person is appointed for each role the LPA must state whether they can make decisions separately or have to make decisions together.
The documents must be registered with the Office of the Public Guardian before they are legally binding.
Care in the last days of life
Identifying patients who are entering the final days of life can be challenging. Care should prioritise the individual's needs and wishes rather than being protocol-driven. Box 2 summarises some of the main practical issues that need to be addressed in the final days of life.
Good communication with the patient, carers and healthcare workers is vital.
Supporting families and carers
The burden of caring for a patient towards the end of life on family and carers is high, and carer breakdown is often a key factor leading to institutionalised care (RCGP, 2012) . Supporting both family and carers is a vital part of palliative care and helps patients to achieve their wishes and reduces the physical and emotional toll on carers.
Carers who are well-supported in their role with access to palliative care services are more likely to be willing to provide such care again . Carers should be fully informed and involved in treatment decisions and taught to care for patients to a level with which they are comfortable. GPs can help by referring carers for assessment and support from social services and pointing them towards self-help groups. Access to 24-hour services and discussions about symptoms that patients may experience and how to manage them, helps to reduce crises. GPs also play a key role in supporting carers in bereavement by offering planned visits, adding consultation alerts to patient notes and referring to bereavement support groups.
KEY POINTS
. People who die from non-malignant disease are less likely to have input from palliative care services and less likely to have discussed ACP
. Failure to identify patients nearing the end of life is a barrier to the provision of appropriate palliative care and support in patients with non-malignant conditions caused by uncertain disease trajectory and lack of clear transition into a terminal phase
. Use of frameworks such as the Gold Standard Framework helps GPs and other healthcare staff to make decisions and provide high-quality end-of-life care
. There is a large overlap in symptom control between patients dying from cancer and patients dying from other illnesses
. ACP can help improve the quality of end-of-life care for patients
. GPs have a key role in giving support to families and carers before and after the death of patients
